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Abstract: Opioid receptor binding conformations for two
structurally related, conformationally constrained tetrapeptides,
JOM-6 (l receptor selective) and JOM-13 (d receptor selective),
were deduced using conformational analysis of these ligands and
analogs with additional conformational restrictions. Docking of
these ligands in their binding conformations to opioid receptor
structural models, based upon the published rhodopsin X-ray
structure, implicates specific structural features of the l and d
receptor ligand binding sites as forming the basis for the l
selectivity of JOM-6 and the d selectivity of JOM-13. In particular,
the presence of E229 in the l receptor (in place of the
corresponding D210 of the d receptor) causes an adverse
electrostatic interaction with C-terminal carboxylate-containing
ligands, resulting in the observed preference of ligands with an
uncharged C-terminus for the l receptor. In addition, the
requirement that the Phe3 side chain of JOM-13 assume a gauche
orientation for optimal d binding, whereas the Phe3 side chain of
JOM-6 must be in a trans orientation for high-affinity l binding
can be largely attributed to the steric effect of replacement of
L300 of the d receptor by W318 of the l receptor. Testing this
hypothesis by examining the binding of JOM-6 and several of its
key analogs with specific l receptor mutants is described. Our
initial results are consistent with the proposed ligand–receptor
interaction models.
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In an effort to understand the details of opioid ligand–
receptor interactions and the basis for observed differences
in ligand structure activity (SAR) profiles at different opioid
receptor subtypes, we have, over the past several years,
followed two complementary paths. The first of these was
directed toward elucidation of the bioactive conformation(s)
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of conformationally restricted ligands selective for indi-
vidual opioid receptor subtypes, while the second path was
focused on the development of a reliable, accurate method
for modeling the three-dimensional structure of the opioid
receptors. Successful completion of these aims would allow
the development of realistic models for the precise inter-
actions of specific opioid ligands with individual opioid
receptor subtypes, from which an understanding of the
structural basis of receptor selectivity could follow. This, in
turn, would provide a reasonable starting point for struc-
ture-based design of more potent and/or more selective
opioid ligands.
Our efforts have been focused primarily on l and d opioid
receptor ligands and have been simplified by the develop-
ment in our laboratory of two structurally related, con-
formationally constrained peptide series that differ
markedly in their d vs. l receptor binding preferences.
Results of conformational analyses, via NMR, X-ray crys-
tallography, and molecular mechanics, as well as struc-
ture)activity differences in these series, which allow
structural features underlying the relative receptor selec-
tivity of the two series to be inferred, are summarized
below. Also summarized below is the method we developed
for structural modeling of the transmembrane 7-helical
bundle of G-protein-coupled receptors (GPCRs) and its
application to the l and d opioid receptors. The more recent
publication of the X-ray structure of rhodopsin, the proto-
typical GPCR, confirmed the primary details of our GPCR
models and allowed an alternative starting point for devel-
opment of l and d receptor models.
Docking ligand bioactive conformation models to the
independently developed receptor models allows hypothe-
ses to be formulated regarding the basis for l vs. d receptor
ligand selectivity. Receptor mutagenesis coupled with spe-
cifically modified ligands provides a means for testing these
hypotheses. Initial studies probing these hypotheses are
presented below.
Development of Opioid Ligand
Pharmacophore Models
As an approach to reduce the flexibility of the backbone of
the d selective cyclic, disulfide-containing peptide, DPDPE
(Tyr-c[d-Pen-Gly-Phe-d-Pen]OH) (1), attributable to its
central glycine residue, a tetrapeptide series in which this
residue was simply eliminated was explored (2). It was
found that this glycine residue, thought to be essential from
early enkephalin SAR studies, could in fact be removed as
evidenced by the high d selective binding affinity displayed
by a key analog in the series, JOM-13 (Tyr-c[d-Cys-Phe-
d-Pen]OH) (2) (Fig. 1). Conformational analysis, using both
experimental and computational approaches, revealed that,
although the 11-membered, tripeptide cycle within JOM-13
is indeed conformationally well defined, the exocyclic Tyr1
residue and the side chain of Phe3, which are key elements
of the opioid pharmacophore, are quite flexible (3). To elu-
cidate the bioactive conformations of these key elements of
ligand)receptor recognition, new series analogs were pre-
pared in which conformationally restricted replacements
for Tyr or Phe were incorporated while maintaining the
11-membered, cyclic scaffold. In the first set of analogs (4),
the Tyr1 residue of JOM-13 was replaced by several con-
formationally constrained analogs of Tyr. Each of these Tyr
replacements has reduced flexibility compared with Tyr
and, importantly, each can sample a different subset of the
conformational space available to Tyr. Consequently, if any
of the analogs examined display similar binding affinity to
JOM-13, then the bioactive conformation of the Tyr1 resi-
due of JOM-13 must lie within the more limited available
conformational space of the Tyr replacement of this more
constrained analog. If two or more of the analogs display
similar binding affinity to JOM-13, then the search for the
bioactive conformational features of Tyr1 in JOM-13 is
simplified to a search within the intersection of conform-
ational space available to the Tyr1 replacements in these
active analogs. This approach proved to be quite successful,
leading to a single proposed bioactive conformation of the
Tyr1 residue of JOM-13 (4). A similar approach was em-
ployed to deduce the side chain conformation of the Phe3
residue when bound to the d receptor (5,6). These studies
indicated that a gauche (v1 ¼ ) 60) conformation is pre-
ferred. Figure 2 shows the proposed bioactive conformation
of JOM-13.
While the JOM-13 series SAR was evolving, we examined
related analogs in which different cyclization approaches
were employed to allow variation in ring size, while
maintaining the d-Cys-Phe-d-Pen tripeptide cycle (2). This
was achieved by cyclizing as a dithioether (rather than the
Figure 1. Structures of JOM-13 and JOM-6.
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disulfide of JOM-13), which allows larger ring sizes to be
readily explored. We discovered that simply replacing the
11-membered disulfide of JOM-13 by a 13-membered ethy-
lene dithioether improved l receptor binding affinity and
decreased d affinity (2). If this peptide is further modified by
replacing the C-terminal carboxylate with a carboxamide
(long known to favor l vs. d binding), the resulting com-
pound, JOM-6 (Tyr-c(S-Et-S)[d-Cys-Phe-d-Pen]NH2) (Fig. 1),
displays high l binding affinity and moderate l selectivity
(2). The combined result of two modifications (changes in
ring size and C-terminus) is a 6000-fold selectivity shift
(JOM-13: Ki (d) ¼ 0.74 nm; Ki (l) ¼ 52 nm. JOM-6: Ki
(d) ¼ 24.8 nm; Ki (l) ¼ 0.29 nm).
Elucidation of the bioactive conformation of JOM-6 at the
l opioid receptor was pursued in the same manner as that of
JOM-6 at the d receptor (7). The resulting proposed bioactive
conformation is shown in Fig. 2, overlaid with the corres-
ponding d receptor binding conformation of JOM-13. As is
evident from the figure, the primary conformational dif-
ference between the two proposed binding conformations is
in the Phe3 side chain. For JOM-13 at the d receptor, as
noted above, the Phe3 side chain assumes a v1 ¼ ) 60
conformation, while for JOM-6 at the l binding site
v1 ¼ 180. The significance of this difference in the context
of structural differences in the l and d binding sites is dis-
cussed below.
Development of Opioid Receptor Structural
Models
Several years ago we began exploring a new approach for the
development of precise structural models of the seven
transmembrane a-helical bundle of GPCRs by computa-
tional refinement of crude structures derived from low-
resolution electron microscopy data and other experimental
results (8). Our approach was based upon the observation
that these transmembrane (TM) helices contain a signifi-
cant fraction of polar residues that must form hydrogen
bonds with other polar side chains or with the helix back-
bone. Analysis of GPCR multisequence alignments allowed
us to assign putative hydrogen-bonding partners and these
collected hydrogen bonds, in turn, served as distance con-
straints for distance geometry calculations, using the pro-
gram diana, that allowed us to arrive at final models for the
GPCR under consideration. The resulting models for rho-
dopsin (8), opioid receptors (9) and  20 additional GPCRs
(10), agree well with experimental data. Indeed, our model
of bovine rhodopsin deposited in the Protein Data Bank
(1bok) superimposes well (11) with the recently determined
rhodopsin crystal structure (12): the rmsd of all 186 com-
mon Ca atoms of the TM domain is 2.8 Å.
We recently developed alternative opioid receptor models
using the rhodopsin X-ray structure as a template for the
inactive state of these receptors. To retain the orientation of
polar, conserved and functionally important residues inside
the TM domain the distortions present in the rhodopsin
structure in TM5 (a-aneurism at H211) and TM7 (2 turns of
3–10 helix near K296) were reproduced in the opioid
receptor models, while the a-aneurism in TM2 (near G90)
was omitted. Because the X-ray structure of rhodopsin
reflects the inactive state of the receptor, structural altera-
tions accompanying activation must be incorporated to
obtain a realistic active-state receptor structure. For exam-
ple, the active state must reproduce the observed changes in
distance between residues V139 (TM3) and C247, C252
(TM6) during rhodopsin activation (13–15). After rotation of
the v2 angle of W265 the binding pocket of the activated
receptor easily adopts the extended structure of the agonist,
all-trans retinal, with the b-ionone ring oriented toward
TM4. We have now employed this activated rhodopsin
model for modeling of active opioid receptors, suitable for
docking of opioid agonists, like JOM-6 and JOM-13. These
homology models agree well with our original distance
geometry models of the l and d receptor and have similar
binding pockets.
Docking of JOM-6 and JOM-13, in their proposed binding
conformations, to the l and d receptors, respectively, was
carried out manually using the quanta molecular mode-
ling software. For both tetrapeptides, Tyr1 was positioned in
the bottom of the pocket to form an ionic interaction
between the ligand N+ and the conserved Asp residue from
Figure 2. Superposition of bioactive conformations of JOM-13 in the d
receptor binding pocket (blue) and JOM-6 in the l receptor pocket (red).
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TM3 (D147 in l, D128 in d), polar interactions with Tyr
from TM7 (Y326 in l, Y308 in d), and H-bonds between the
ligand Tyr1 OH groups and a conserved Tyr from TM3 and
His from TM6 (Y147 and H297 in l, Y129 and H278 in d).
The importance of these four conserved residues of
the binding pocket has been demonstrated by mutagenesis
(16–20).
Figures 3 and 4 show the results of docking of JOM-13 to
the d and JOM-6 to the l opioid receptor, respectively. Each
figure also shows, in thin lines, the corresponding location
of the other ligand in its receptor binding site. The inter-
actions displayed in these figures represent an abridged
subset, meant to highlight the anchoring interactions noted
above and interactions that, because of sequence differences
between the l and d receptors, underlie the selectivity dif-
ferences between JOM-13 and JOM-6. Notable in the latter
category are differences in the regions of the l and d binding
pockets that interact with the ligand C-terminus and the
ligand Phe3 side chain.
Structural Basis of l vs. d Selectivity
Receptor environment of ligand C-terminus
It can be seen in Figs 3 and 4 that the environment of the
ligand C-terminus of JOM-13 in the d binding site and JOM-
6 in the l binding site differ slightly in our two ligand–
receptor interaction models. As seen in Fig. 3, the amine-
containing side chain of K214 (TM5) of the d receptor forms
an ionic interaction with the C-terminal carboxylate of
JOM-13, consistent with the observation that a negatively
charged C-terminus enhances ligand affinity for the d
receptor. Figure 4 demonstrates that the longer cycle of
JOM-6 leads to a slightly different positioning of the ligand
C-terminus, slightly farther from the corresponding l
receptor residue, K233. In this case, the K233 interacts,
instead, with the receptor E229 residue. In the d receptor,
the residue corresponding to the l receptor’s E229 is D210.
In our ligand–receptor interaction models, the longer side
chain of the E229 (compared with the d receptor’s D210) and
the shifted location of the ligand C-terminus in the two
receptors results in a closer proximity between these groups
in the l binding site. Because of this proximity, C-terminal
carboxylic acid-containing ligands encounter ionic repul-
sion at the l binding site, resulting in lower affinity. This is
entirely consistent with a large body of structure activity
data for l ligands.
To test this aspect of our binding models, the binding
affinities of JOM-6 and JOM-18 (Tyr-c(S-Et-S)[d-Cys-Phe-
d-Pen]OH), in which the C-terminal carboxamide of JOM-6
is replaced by a carboxylate, were determined. Binding to
both the wild-type l opioid receptor and the E229D l
receptor mutant was examined. Our ligand–l receptor
interaction model would predict that JOM-18 should bind
poorly to the wild-type l receptor because of ionic repul-
sion, but that this effect should be less dramatic in the
E229D mutant, as the shorter Asp side chain attenuates this
repulsion. Table 1 summarizes the results of these binding
assays. As expected, binding of JOM-18 to the wild-type l
receptor is poor; compared with JOM-6, the affinity of
JOM-18 is reduced  4400-fold. By contrast, JOM-18 bind-
ing to the E229D l receptor mutant is an order of magnitude
Figure 3. JOM-13 (blue) in d receptor binding site (thick lines). JOM-6
(thin red lines) in l binding site (thin lines) is also depicted.
Figure 4. JOM-6 (red) in l receptor binding site (thick lines). JOM-13
(thin blue lines) in d binding site (thin lines) is also depicted.
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stronger than to wild-type, and is only 90-fold weaker than
that of JOM-6. Thus compared with JOM-6 (whose affinity
decreases > 6-fold owing to the E229D mutation), the rel-
ative binding affinity of JOM-18 improves 50-fold when
E229 is mutated to Asp. This strongly supports our binding
interaction model and implies that the change from D210
in the d receptor to the corresponding E229 in l is chiefly
responsible for the well documented difference in receptor
preference of opioid peptides with anionic vs. neutral
C-terminal groups.
Receptor environment of Phe3 side chain
Examination of Figs 3 and 4 suggests the basis for the ob-
served difference in Phe3 side chain orientation preference
at the d vs. l opioid receptors. As depicted in Fig. 3 our
models predict that a gauche (v1 ¼ ) 60) orientation of
Phe3 of JOM-13 is favored because it places the Phe3 side
chain in a nonpolar region of the receptor, near L300. JOM-6
in the l receptor binding site interacts with the corres-
ponding receptor residue, W318. However, because of the
slightly shifted orientation of JOM-6 in its binding site, this
interaction requires that the JOM-6 Phe3 side chain be in a
trans (v1 ¼ 180) orientation. The binding models are con-
sistent with the observation that [DZPhe3]JOM-13, in which
the residue 3 side chain is constrained in a gauche-like
orientation, binds much better to the d receptor than does
[DEPhe3]JOM-13, in which the residue 3 side chain is trans,
and with the observation that the opposite preferences are
observed for the corresponding JOM-6 analogs binding to
the l receptor.
Our models suggest that the replacement of the d receptor
L300 by W318 in l is critical for the favorable l binding of
JOM-6, because the bulkier Leu residue would result in
adverse steric interactions with the trans Phe3 rotamer.
This prediction was evaluated by examining the binding of
[DEPhe3]JOM-6 and [DZPhe3]JOM-6 to the wild-type l opioid
receptor and to the W318L mutant. If our model is correct,
the W318L mutation should block optimal interaction of
the DEPhe3 side chain, resulting in diminished binding
affinity of [DEPhe3]JOM-6, while the mutation should have
little effect on the binding of [DZPhe3]JOM-6, as the gauche-
like orientation of the DZPhe3 interacts poorly with either
W318 or its Leu replacement, due to the shift of the ligand
in the l binding site. Results shown in Table 1 are consis-
tent with these predictions. As predicted, the binding of
[DZPhe3]JOM-6 is weak to both wild-type and mutant l
receptor, with similar affinities observed for the two
receptors. In contrast, [DEPhe3]JOM-6, which binds well to
the wild-type l receptor, displays a > 100-fold reduction in
affinity to the W318L mutant.
While falling short of unequivocally proving our ligand–
receptor interaction models, the results described above
clearly provide support for these models and provide valu-
able insights into the basis of ligand selectivity at l and d
opioid receptors. Further validation of the models is in
progress as is structure-based ligand design using the mod-
els as the foundation.
Experimental Procedures
Materials
The pCMV expression vectors containing the coding
sequence for the l opioid receptor were obtained from
Professor Huda Akil at the University of Michigan. Pfu
turbo DNA polymerase, DpnI restriction endonuclease and
XL1-blue super-competent E. coli cells were purchased
from Stratagene. Nucleotide primers, antibiotics, 1 m
Tris)HCl buffer, Lipofectamine Plus reagent and cell
culture media and reagents were purchased from Life
Technologies. [3H] DAMGO was purchased from NEN.
Ninety-six-well glass-fiber filter plates were purchased from
Millipore. Protected amino acids, reagents and resins for
peptide synthesis were obtained from Advanced Chem-
Tech, or Peptides International. All other reagents were
from Sigma-Aldrich unless otherwise indicated.
Peptide synthesis
All peptides were prepared using standard solid-phase
methods similar to those described previously for the syn-
thesis of JOM-6 (2), using chloromethylated polystyrene
(Merrifield) resin cross-linked with 1% divinylbenzene.
Table 1. Binding affinities of JOM-6 analogs to wild-type and












For each Ki value, SEM was < 10%. KD values for
[3H]DAMGO: 1.1 nM (MOR); 1.4 nM (E229D); 0.94
(W319L).
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Trifluoroacetic acid (TFA) was used for deprotection, and
dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotria-
zole (HOBt) were employed to facilitate coupling. Alpha-
amino functions were t-butyloxycarbonyl (Boc) protected,
and p-methylbenzene protection was employed for the
labile side chain sulfhydyl groups of Cys and Pen. Simul-
taneous deprotection and cleavage from the resin were
accomplished by treatment with anhydrous hydrogen
fluoride in the presence of 5% p-cresol and 5% p-thiocresol.
Cyclization to dithioether-containing analogs was accom-
plished by treatment of a dilute solution of the linear free
sulfhydryl-containing species in dimethyl formamide with
potassium tert-butoxide followed by addition of dibromo-
ethane. All peptides were then purified by RP-HPLC. Final
product confirmation was obtained by fast atom bombard-
ment mass spectrometry (FAB-MS).
Site-directed mutagenesis
Single, double and triple point mutations of the l opioid
receptor were generated from the l/pCMV expression
vector using the QuickChange Mutagenesis Kit (Stratagene,
La Jolla, CA, USA). Each mutation was verified by DNA
sequencing.
Cell culture and transfection
Cos-1 cells were grown in Dulbecco’s modified Eagle’s
medium (high glucose) supplemented with 10% FBS and
incubated at 37C in 5% CO2. At 80% confluency, the cells
were transiently transfected with 8–10 lg per 75 cm2 flask
of the wild-type and l opioid/pCMV mutants using Lipo-
fectamine Plus reagent (20 and 30 lL of Plus reagent and
Lipofectamine, respectively).
Cos-1 membranes
Forty-eight hours after transfection, the Cos-1 membranes
were prepared for assay as described previously (21). Briefly,
the Cos-1 cells were scraped into 50 mm Tris)HC1, pH 7.4
containing 0.1 lg/mL PMSF (ice-cold) and homogenized
using a Polytron homogenizer. Following centrifugation at
15 000 g for 30 min at 4C, the membranes were resus-
pended to a concentration of 0.2 lg/mL in the homogeni-
zation buffer.
Radioligand binding assays
We used 40–50 lg of the membrane preparations in
200 lL for all binding studies. For all binding assays, the
membranes were incubated with 25 lL aliquots of [3H]
DAMGO in 50 mm Tris)HC1, pH 7.4 in 96-well poly-
propylene microtiter plates. 0.1–20 nm of the radioligands
was used for saturation binding studies. Competition
binding assays were carried out in the presence of 2 nm
radioligand and 0.1 nm to 30 lm of peptide ligands. Non-
specific binding was determined in the presence of 2 lm
unlabeled Naloxone. After incubating for 1.5 h at room
temperature, the samples were transferred to 96-well
glass-fiber filter plates, filtered, and washed with
2 · 200 lL ice-cold 50 mm Tris)HC1, pH 7.4. Filter plates
were counted using a Wallac Trilux1450 Microbeta scin-
tillation counter.
Data analysis
Saturation binding results were analyzed and Kd values for
the wild-type and receptor mutants were determined using
the ligand program. Competition binding curves were
analyzed by nonlinear regression using sigmaplot 7.0
(SPSS Science, Chicago, IL, USA), and IC50 values were
converted to Ki values using the Cheng-Prusoff correction
(22).
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